Topic Listing for Acorda Therapeutics

Accounting Certain Financial Instruments Characteristics Liabilities Equity Accounting Certain Investments Debt Equity Securities
Accounting Consideration Given Vendor Customer Accounting Derivatives Instruments Hedging Activities
Accounting Impairment Disposal Long-lived Assets Accounting Income Taxes
Accounting Stock Appreciation Rights Other Variable Option Award Accounting Stock-based Compensation
Accounting Stock-based Compensation Transition Disclosure Amendment Fasb Statement Accrued Expenses Other Current Liabilities
Acorda Conference Call Today 530 Eastern Time Acorda Party Agreement Terms
Acorda Supply Agreements Acorda Therapeutics
Acorda Therapeutics Announces Adrian Rabinowicz Joins Senior Vice Acorda Therapeutics Announces Completion Enrollment Fampridine-sr Clinical Trial
Acorda Therapeutics Announces Completion Zanaflex Capsules Sales Force Acorda Therapeutics Announces Directors Stepping Down
Acorda Therapeutics Announces Exercise Option Underwriters Acorda Therapeutics Announces Interim Analysis Two-year Efficacy Safety
Acorda Therapeutics Announces Lauren Sabella Joins Executive Vice Acorda Therapeutics Announces Positive Results Phase Study Fampridine-
Acorda Therapeutics Announces Positive Vote Fda Advisory Committee Acorda Therapeutics Announces Pricing Patient Assistance Programs Ampyra
Acorda Therapeutics Announces Receipt Anda Filing Zanaflex Capsules Acorda Therapeutics Announces Resignation Mary Fisher
Acorda Therapeutics Announces Successful Thorough Study Fampridine-sr Acorda Therapeutics Completes Enrollment Phase Clinical Trial Fampridine-sr
Acorda Therapeutics Elects Barry Greene Coo Alnylam Board Acorda Therapeutics Elects John Kelley Board Directors
Acorda Therapeutics Fda Reach Agreement Special Protocol Assessment Acorda Therapeutics Files Lawsuit Against Apotex Corp Inc
Acorda Therapeutics Inc Acorda Therapeutics Inc 2009 Form 10-k Annual Report
Acorda Therapeutics Inc Announces Exercise Option Underwriter Acorda Therapeutics Inc Announces Exercise Option Underwriters
Acorda Therapeutics Inc Announces Pricing Common Stock Offering Acorda Therapeutics Inc Announces Pricing Public Offering Common
Acorda Therapeutics Inc Announces Proposed Public Offering Common Acorda Therapeutics Inc Forward-looking Statements
Acorda Therapeutics Inc Skyline Drive Hawthorne New York Acorda Therapeutics Inc Table Contents
Acorda Therapeutics Names Ian Smith Cfo Vertex Board Acorda Therapeutics Presents Data Phase Study Fampridine-sr Multiple
Acorda Therapeutics Presents Positive Data Preclinical Studies Neuregulins Acorda Therapeutics Provides Update Clinical Development Fampridine-sr
Acorda Therapeutics Receives Additional Paul Capital Healthcare Acorda Therapeutics Reports 2006 Financial Results
Acorda Therapeutics Reports 2007 Financial Results Acorda Therapeutics Reports 2008 Financial Results
Acorda Therapeutics Reports 2009 Financial Results Acorda Therapeutics Reports Date Fda Advisory Committee Review
Acorda Therapeutics Reports Full 2005 Financial Results Acorda Therapeutics Reports Full 2006 Financial Results
Acorda Therapeutics Reports Full 2007 Financial Results Acorda Therapeutics Reports Full 2008 Financial Results
Acorda Therapeutics Responds Point Letter Acorda Therapeutics Resubmits New Drug Application Fampridine-sr Improvement
Acorda Therapeutics Stock Trading Halted Today Fda Advisory Acorda Therapeutics Submits New Drug Application Fampridine-sr Improvement
Additional Information Find Additional Powers
Additional Studies Required Fda Fampridine-sr Not Yield Favorable Additional Studies Required Fda Unable Obtain Regulatory Approval
Advance Pipeline Preclinical Programs Clinical Trials Advise Holders
Advisory Fiduciary Responsibility Affiliate Assignment Not Accordance Foregoing Shall Void Subject
Agreement License Each Party Free Pursue Rights Available Allowance Doubtful Accounts
Amended Restated License Amendment
Amendment 101 Amendment 2005 Employment Agreement
Amendment 203 Amendment 406
Amendment 502 Amendment 508
Amendment 515 Amendment Revenue Interests Assignment Agreement Guaranty
Amendments Amendments Articles Incorporation Bylaws Change
Amendments Revenue Agreement Guaranty Aminopyridine Pre-clinical Assets Neurorecovery Inc
Ampyra Ampyra Dalfampridine
Ampyra Patient Support Services Andrew Blight Phd
Annual Jpmorgan Healthcare Conference Annual Report
Answer Yes Question Below Application Issue 98-5 Certain Convertible Instruments
Approach Market Cns Disorders Attached
Attendance Board Committee Meetings Audit Committee Financial Experts
Audit Committee Report Authority
Average Blood Concentrations Tizanidine Subjects Following Single Dose Average Plasma Concentrations Tizanidine Subjects Following Single Dose
Background Barclay Phillips
Barry Greene Base Salary
Because Not Intend Pay Dividends Benefit Investment Common Because Not Intend Pay Dividends Foreseeable Future Benefit
Beneficial Conversion Feature Beneficial Conversion Feature Accretion Issuance Costs Preferred Dividends
Beneficial Owner Beneficial Ownership Reporting Compliance
Benefit Plans Between
Binding Effect Assignment Biogen Idec
Biogen Idec Acorda Therapeutics Announce Collaboration Agreement Develop Biogen Idec Contacts
Biological Hazardous Materials Manner Causes Injury Liable Damages Board Committee Fees
Board Directors Recommends Stockholders Vote Proposal Boston 2007
Cambridge University Technical Services Limited Kings College London Canadian Spinal Research Organization
Cannot Protect Intellectual Property Ability Develop Commercialize Products Cannot Protect Maintain Necessary Enforce Intellectual Property Ability
Capital Stock Cardinal Health Pts Llc
Cash Bonus Program Cash Equivalents
Cenes Pharmaceuticals Plc Centralized Review Europe
Certain Provisions Delaware Law Certificate Incorporation By-laws Delay Certain Provisions Delaware Law Certificate Incorporation Bylaws Delay
Certain Relationships Related Transactions Certification Chief Executive Officer Pursuant Rule 13a-14 Securities
Certification Chief Financial Officer Pursuant Rule 13a-14 Securities Certification Pursuant Usc 1350 Acorda Therapeutics Inc Adopted
Chair Challenge Nervous System Disorders
Change Internal Control Over Financial Reporting Change Walking Speed Over Time
Charter Chondroitinase
Chondroitinase Program Clinical Studies
Clinical Studies Safety Profile Clinical Trials Fampridine-sr
Clinical Trials Multiple Sclerosis Clinical Trials Spinal Cord Injury
Co-pay Program Implemented Help Manage Out-of-pocket Expenses Code Ethics
Code Interactions Healthcare Professionals Collaboration Agreement
Collaboration Partner Biogen Idec Need Obtain Regulatory Approval Commercialization Metrics Forecast
Commercially Reasonable Efforts Obtain Withdrawal Order Suspending Effectiveness Commitments Contingencies
Committees Board Directors Common Stock Options Restricted
Compared 2002 Compared 2004
Compared 2005 Compared 2006
Compared 2007 Compared 2008
Compensation Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Discussion Analysis Compensation Philosophy Objectives
Competition Competitors Develop Market Products Effective Safer Convenient Approved
Complete Clinical Development Obtain Regulatory Approval Fampridine-sr Completed Phase Trial
Completed Phase Trials Multiple Sclerosis Compliance 409a
Compliance Committee Compliance Program Guidance Pharmaceutical Manufacturers
Comprehensive Income Comprehensive Income Loss
Concentration Risk Condition Precedent
Conditions Closing Conditions Obligations Underwriters
Conference Call Conference Call Audio Webcast
Conference Call Audiocast Conference Call Webcast
Confidential Conflict
Consent Consent Independent Registered Public Accounting Firm
Consent Sublicense Certain Acordas Rights Above Amended Restated Contact
Contacts Continuing Effect
Contract Pharmaceutical Telesales Organization Contract Sales Force Primary Care Physicians
Contractual Obligations Commitments Contribution
Controls Controls Procedures
Convertible Cornell Research Foundation Inc
Corporate Corporate Earnings Schedule
Corporate Highlights Corporate Information
Corporate Power Authorization Binding Effect Corporate Update
Cost Sales Counterparts
Covenants Covington Burling Counsel Dated Such Closing Date Subsequent
Creation Direct Financial Obligation Off-balance Sheet Arrangement Critical Accounting Policies Estimates
Cumulative Effect Change Accounting Principle Current Phase Trial
Current Report Currently Manufacturing Capabilities Substantially Dependent Elan Novartis Other
Currently Manufacturing Capabilities Substantially Dependent Elan Other Party David Lawrence
David Lawrence Mba Default Several Underwriters
Definitions Definitions Following Capitalized Terms Meanings
Departure Directors Principal Officers Election Appointment Departure Directors Principal Officers Election Appointment Compensatory
Dependent Collaboration Biogen Idec Commercialize Ampyra Outside Dependent License Agreements Fail Meet Obligations Terminated Reason
Director Compensation Director Executive Compensation
Director Independence Director Officers Subject Lock-up Agreements
Director Qualifications Nomination Process Directors
Directors Executive Officers Registrant Directors Whose Terms Expire 2008-class
Directors Whose Terms Expire 2009-class Directors Whose Terms Expire 2010-class
Discounts Allowances Discussion Audited Financial Statements
Disease Course Management Dividend Policy
Dividends Documents Incorporated Reference
Drug Development Programs Early Stages Never Commercialized Earnings Per Share
Effectiveness Agreement Effects Inflation
Elan Elan Corporation Plc
Elan Drug Technologies Elan Milestones
Elements Compensation Employee Benefit Plan
Employees Employment Agreements Change Control
Entry Material Definitive Agreement Equity Awards
Equity Compensation Equity Compensation Plans
Erica Wishner Acorda Therapeutics Director Corporate Communications Estimates
Evaluation Disclosure Controls Procedures Event Date Time Aug 2006 830am
Executive Compensation Executive Employment Agreements
Executive Officer Severance Plans Exhibits
Expand Business Through Acquisition Companies Businesses In-licensing Product Expect Further Increase Sales Force Anticipation Possible Launch
Expenses Offering Experience Pressure Lower Prices Approved Products Due New
Explanatory Face Inherent Risk Liability Event Misuse Products Results
Failure Selling Stockholders Sell Deliver Common Shares Fair Value Financial Instruments
Fair Value Measurements Fampridine-sr
Fampridine-sr Clinical Trials Updates Fampridine-sr Clinical Update
Fampridine-sr Data Presentations Medical Meetings Fampridine-sr Highlights
Fampridine-sr Mechanism Action Fampridine-sr Pdufa Goal Date 2010
Fampridine-sr Regulatory Update Fampridine-sr Scientific Update
Fampridine-sr Update Fampridine-sr Updates
Fampridine-sr Walking Ability People Multiple Sclerosis Fda Advisory Committee Meeting Fampridine-sr
Fda Extends Fampridine-sr Pdufa Goal Date 2010 Fda Regulation Product Approval
Fda-approved Product Labeling Ampyra Limited Adversely Affect Market Figure Average Blood Concentration Over Time
Figure Average Change Walking Scale Score Figure Average Percent Change Baseline Walking Speed
Figure Average Plasma Concentration Over Time Figure Design Fampridine-sr Ms-f202 Phase Clinical Trial
Figure Ms-f202 Average Change Baseline Lemmt Figure Responder Rates Treatment Groups Ms-f202
Figure Summary Study Results Spa Criteria Intent Treat Figure Summary Study Results Spa Criteria Itt Population
Financial Literacy Financial Results
Financial Results Product Update Financial Statements Exhibits
Financial Statements Supplementary Data Financing Arrangements
Following Documents Being Filed Part Report Foreign Regulation Product Approval
Form 10-k Form 10-q
Forward Looking Statements Forward-looking Statement
Forward-looking Statements Fulfilling Obligations Pursuant Compliance Sarbanes-oxley Act 2002 Expensive
Full 2009 Financial Guidance Further Provisions
Future Capital Needs Future Sales Common Stock Cause Price Decline
General General Administrative
General Administrative Expenses General Provisions
Generic Drugs Ratings Pharmacy Substitution Ggf2
Good Reason Governing Law Jurisdiction
Governing Law Miscellaneous Governing Law Provisions
Governmental Prohibition Sale Shares Shall Not Prohibited Law Grant Revenue
Grants Plan-based Awards Table Graph Depicts Average Change Walking Speed Treatment Period
Gross Sales Harris Interactive
Hawthorne 2006 Hawthorne 2007
Hawthorne 2008 Hawthorne 2009
Hawthorne New York 2006 Headings
Headings Agreement Convenience Reference Only Not Part Affect Highlights
Highly Dependent Commercial Success Ampyra Foreseeable Future Unable Histogram Show Average Change Score Walking Scale Responders
History Operating Losses Expect Continue Incur Never Profitable Host Conference Call 830 Eastern Time Today
Householding Http Wwwacordacom
Ian Smith Identification Evaluation Director Candidates
Immediate Release Impairment Long-lived Assets
Important Safety Information Income Taxes
Incur Significant Liability Determined Promoting Off-label Ampyra Other Independence
Independent Advisors Independent Auditor Review Interim Financial Statements
Index Index Financial Statements
Information Concerning Directors Information Concerning Executive Officers
Initial Public Offering Private Placement Common Stock Intangible Assets
Intellectual Property Internal Specialty Sales Force
Introductory Inventory
Investigations Investment Activities
Jane Wasman Joel Sendek Lazard Capital Markets Analyst
John Friedman Leg Strength
Legal Proceedings Leverage Commercial Presence Zanaflex Capsules Potential Launch Fampridine-sr
License Revenue Cost Limitations Effectiveness Controls
Limited Net Amount Received Holder Sale Registrable Securities Limited Sales Marketing Experience Not Successful Building Effective
Liquidation Liquidity Capital Resources
Lorin Randall Loss Key Management Scientific Personnel Hinder Ability Execute
Managements Report Internal Control Over Financial Reporting Mandatorily Redeemable Convertible Preferred Stock
Manufacturing Capabilities Dependent Elan Other Party Suppliers Manufacture Marion Glick Porter Novelli 212-601-8273 Cell 917-301-4206 Email
Mary Fisher Mary Fisher Acorda Therapeutics Coo
Maximize Revenue Opportunity Zanaflex Capsules Mayo Foundation Medical Education Research
Meaning Other-than-temporary Impairment Application Certain Investments Measurement Walking Disability
Meetings Minority Interest
Ms-f201 Study Ms-f202 Study
Ms-f204 Ms-f204 Trial Design
Multiple Sclerosis Multiple Sclerosis Demonstrated Increases Walking Speed
National Society Need Obtain Regulatory Approval Foreign Jurisdictions Seek Market
Net Cash Provided Financing Net Cash Provided Investing
Net Cash Provided Used Operations Net Cash Used Financing
Net Cash Used Investing Net Cash Used Operations
Net Cash Used Provided Financing Net Cash Used Provided Investing
Neuregulins Neuregulins Ggf-2
Neuregulins Ggf2 Neurology
New Accounting Pronouncement New Drug Application Filing
Nine-month Period 2006 Compared 2005 Nine-month Period 2007 Compared 2006
Nine-month Period 2008 Compared 2007 Nine-month Period 2009 Compared 2008
Nominations Committee Nominees Standing Election Term Expiring 2010-class Directors
Nominees Standing Election Term Expiring 2011-class Directors Not Applicable
Not Maintain Effectiveness Registration Statements Covering Resale Shares Notes Payable
Notice Annual Meeting Stockholders Notices
Notified Food Drug Administration Fda Advisory Committee Meeting Now Therefore
Number Number 000-50513
Number Price Common Shares Offerings Common Stock
Officers Officers Directors Largest Stockholders Choose Act Together They
Ongoing Zanaflex Capsule Tablet Sales Operations Curtailed Unable Obtain Necessary Additional Financing Favorable
Option Exercises Stock Vested Organization Business Activities
Orphan Drugs Other Business
Other Compensation Other Disorders Central Nervous System
Other Drug Development Products Undergo Rigorous Clinical Testing Other Drug Development Programs Early Stages Never Commercialized
Other Events Other Expense
Other Expense Net Other Income Expense
Other Information Other Regulations
Others Identify Previously Unknown Side Effects Ampyra Known Outlook
Outstanding Equity Awards 2007 Oversight
Oversight Independent Auditors Overview
Ownership Securities Changes Between Date Hereof Filing Registration Parent Guaranty
Partial Unenforceability Parties Successfully Claim Infringed Patents Proprietary Rights Ability
Patient Information Line Paul Capital Healthcare
Paul Capital Partners Healthcare Payment Expenses
Pending Knowledge Threatened Challenges Right Subsidiary Respect Intellectual People Extremely Concerned Impairment Walking Ability Physicians Rank
Pharmaceutical Industry Subject Stringent Regulation Failure Obtain Regulatory Pharmacokinetic Differences Between Zanaflex Capsules Tizanidine Tablets
Phase Phase Clinical Trials
Phase Clinical Trials Fampridine-sr Unsuccessful Unable Obtain Regulatory Phase Fampridine-sr Extension Studies
Phil Nadeau Cowen Analyst Planned Initial Public Offering Costs
Please Complete Sign Date Return Accompanying Proxy Enclosed Post-approval Regulation
Potential Payments Termination Change Control Potential Products Not Commercially Viable Fail Obtain Adequate
Power Authorization Binding Effect Pre-approval Policies Procedures
Pre-launch Activities Update Preapproval Services
Preclinical Pipeline Updates Preclinical Product Update
Preclinical Products Preclinical Update
Presentation Highlights Presentation Replay
President Chief Operating Officer Medicines Nasdaq Mdco Been Press Release
Principal Accountant Fees Services Principles Consolidation
Priority Review Granted 2009 Pdufa Date Procedures Complaints
Proceeds Registered Securities Product Candidates Undergo Rigorous Clinical Testing Results Uncertain
Product Pipeline Product Returns
Product Revenue Returns Products Product Candidates Not Gain Market Acceptance Among
Products Product Pipeline Properties
Properties Applicable Except Respect Clauses Only Such Violations Property Equipment
Proposal Proposal Election Directors
Proposed Trade Name Fampridine-sr Approved Amaya Prospectus Amendment Supplement Thereto Agreement Effect
Purchase Sale Shares Purchasers Representations Warranties
Purpose Pursuant Securities Exchange Act 1934
Pursue Additional Alliances Approved Development Stage Products Qualifications Director Candidates
Quantitative Qualitative Disclosures Market Risk Quarterly Consolidated Financial Data
Questions Answers Proxy Materials 2007 Annual Meeting Stockholders Ratification Appointment Kpmg Llp
Recent Accounting Pronouncements Recent Highlights
Recently Expanded Sales Force Zanaflex Capsules Not Grow Recently Expanded Sales Managed Markets Marketing Organization Not
Recently Issued Accounting Standards Recitals
Reclassification Recognized Revenue Reported
Recommendation Board Regarding Financial Statements Reconciliation Gaap Net Loss Adjusted
Redemption References
Registration Rights Registration Statement Issuer Free Writing Prospectus Preliminary Amendment
Regulation Disclosure Regulation Disclosures
Reimbursement Pricing Controls Reimbursement Underwriters Expenses
Relapse Management Related-party Transactions
Rely Parties Provide Sales Representatives Market Zanaflex Capsules Remainder Page Intentionally Left Blank
Remyelinating Antibodies Remyelinating Antibodies Program
Remyelination Programs Reorganization Event
Report Independent Registered Public Accounting Firm Reporting Comprehensive Income
Representations Indemnities Survive Delivery Representations Warranties
Representations Warranties King George Holdings Luxembourg Iia Requirements Including Deadlines Submission Proxy Proposals Nomination Directors
Research Development Research Development Expenses
Research Development-related Party Residency Purchaser Resident Jurisdiction Set Forth Immediately
Restricted Cash Restricted Stock
Restricted Stock Activity Results Operations Financial Condition
Returns Zanaflex Tablets Adversely Affect Results Operations Returns Zanaflex Tablets Sold Elan
Revenue Recognition Revenue Recognition Right Return Exists
Revenue Recognition-grants Review Audited Financial Statements
Review Other Financial Statements Disclosures Rhigm22
Risk Factors Ron Cohen
Rule 14a-101 Rush-presbyterian Lukes Medical Center
Safety Efficacy Results Safety Profile Fampridine-sr
Safety Statement Sale Revenue Interest
Sale Zanaflex Tablet Inventory Acquired Elan Sales Future Revenues
Sales Marketing Sales Marketing Expenses
Sales Marketing Managed Markets Sales Promotional Support Zanaflex Capsules
Sandra Panem Phd Schedule
Schedule 14a Rule 14a-101 Schedule Free Writing Prospectuses Included Disclosure Package
Sci Scientific Medical Network
Sec Timely Manner Reports Other Documents Required Exchange Securities Amendment Agreement
Securities Registered Pursuant Act Security Ownership Certain Beneficial Owners Management Related Stockholder
Seek Market Products Foreign Jurisdictions Need Obtain Regulatory Segment Information
Selection Selection Removal
Series Series Preferred Stock Purchase
Setting Executive Compensation Severability
Shall Not Been Change Decrease Specified Letter Letters Share Based Compensation
Share-based Compensation Short-term Investments
Signatures Signatures Appear Following Page
Significant Events 2007 2008 Date Significant Events 2008 2009 Date
Six-month Period 2006 Compared 2005 Six-month Period 2007 Compared 2006
Six-month Period 2008 Compared 2007 Six-month Period 2009 Compared 2008
Skyline Drive Hawthorne New York 10532 Skyline Drive Hawthorne New York 10532 914 347-4300
Spasticity Special Protocol Assessment Spa
Specialty Pharmacies Rely Sell Ampyra Fail Perform Business Spinal Cord Injury
Standish Fleming State Pharmaceutical Compliance Reporting Requirements Expose Regulatory Legal
State Pharmaceutical Marketing Compliance Reporting Requirements Expose Regulatory Statement Cash Flows
Steven Rauscher Stock Option Activity
Stock Option Information 2006 Stock Options
Stock Price Performance Graph Stock Price Volatile Lose Part Investment
Stock-based Compensation Stockholder Communication Board Directors
Stockholder Recommendations Director Candidates Stockholder Record
Strategy Stroke
Structure Membership Study
Study Design Subcommittees
Subject Penalties Fail Comply Post-approval Legal Regulatory Requirements Subject Various Federal State Laws Regulating Marketing Zanaflex
Submission Matters Vote Security Holders Subsequent Events
Substantially Dependent Sales Product Zanaflex Capsules Generate Revenue Successors
Supply Agreement Symptom Relief
Table Contents Tax Accounting Considerations
Termination Termination Agreement
Termination Assignment Agreement Termination Employment Cause Without Good Reason
Termination Employment Without Cause Voluntary Good Reason Termination Employment Without Cause Voluntary Good Reason Following
Termination Material Definitive Agreement Teva Collaboration Agreement
Teva Pharmaceuticals Industries Ltd Teven Rauscher
Thank Thanks Erica Welcome Everyone Call Morning
Thanks Ron Third-party Contract Research Organizations Not Perform Acceptable Timely
Three-month Period 2006 Compared 2005 Three-month Period 2007 Compared 2006
Three-month Period 2008 Compared 2007 Three-month Period 2009 Compared 2008
Trademarks Transactions Greater Stockholders
Transfer Resale Purchaser Understands Trial Design
Unable Obtain Regulatory Approval Fampridine-sr European Union Other Unable Obtain Regulatory Approval Fampridine-sr Unduly Limited Scope
Unable Successfully Differentiate Zanaflex Capsules Tablets Generic Tizanidine Unregistered Sales Equity Securities
Vacation Vote Mail
Voting Waiver
Warrants Webcast
Webcast Conference Call Whereas
Wise Young Phd Zanaflex
Zanaflex Capsules Zanaflex Capsules Highlights
Zanaflex Capsules Sales Force Zanaflex Capsules Updates
Zanaflex Products 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki